‼️REPRIEVE Trial ppl wHIV at low ASCVD risk have >coronary plaque vs asympt ppl in #SCAPIS = plaque as stable chest pain #PROMISE pts w/oHIV on #CCT ‼️ppl wHIV have ⬆️nonCalc plaque▶️CAC=0 may not rule out CAD JACC Journals #JACCAdvances 📌 jacc.org/doi/10.1016/j.… Michael Lu

‼️read the accompanying editorial by the amazing Ronak Rajani Ronak Rajani highlighting important contextual elements and clinically relevant takeaways 📌 jacc.org/doi/10.1016/j.…

Learn more about REPRIEVE team member Gerald Bloomfield in this recent feature by Duke Global Health Dr. Bloomfield, we are grateful for all that you do for REPRIEVE and beyond!

Current or previous use of the antiretroviral drug abacavir was associated with an elevated risk of major adverse cardiovascular events in people with #HIV, according to an exploratory analysis from the #NIH funded @REPRIEVETrial. Learn more: go.nih.gov/axDEMGx

Today is National HIV/AIDS & Aging Awareness Day, a day to address the impact of #HIV on adults aged 50 and older. We can #StopHIVTogether by reducing HIV stigma and promoting HIV prevention and treatment for older adults. cdc.gov/stophivtogether #NHAAD

#HotOffThePress The REPRIEVE Team published important new data on risk factors for #diabetes among people with HIV. To learn more, visit doi.org/10.7326/ANNALS… @nih_nhlbi NIAID News ACTG Network MassGeneral Medicine Harvard CBAR

In a new study published in Annals of Int Med, researchers from MGH Metabolism Unit REPRIEVE Trial and colleagues investigated metabolic risk factors for new-onset diabetes among people with #HIV. Read more: massgeneral.org/news/research-… Steve Grinspoon Brigham and Women’s Infectious Diseases

A #NewPublication from the REPRIEVE Team reports that among PWH, statin therapy showed potential to reduce the risk of serious COVID-19. Read the full article in Clinical Infectious Diseases: doi.org/10.1093/ofid/o… MassGeneral Medicine @nih_nhlbi NIAID News Harvard CBAR ACTG Network

ACTG studies on aging highlighted at the #HIVAging Workshop! ACTG Network REPRIEVE Trial Evelyn Iriarte Grace Ditzenberger

On Trans Day of Remembrance, founded in 1999, we honor those shining lights lost too soon to anti-trans violence. 🏳️‍⚧️ #TDoR Trans youth deserve to become thriving trans adults. 🏳️‍⚧️ #TransLivesMatter

Despite incredible advances made in the treatment of #HIV, there is still far too much stigma and misinformation surrounding the subject. Here are five facts about HIV which are vital to understanding this #WorldAIDSDay #UequalsU #CantPassItOn

#HotOffThePress This REPRIEVE manuscript showing that baseline statin use may protect against severe COVID-19 received an editorial in OFID! Read the editorial here: doi.org/10.1093/ofid/o… Thank you to @EricMeyerowitz, Arthur Kim, and Open Forum Infectious Diseases! @nih_nhlbi NIAID News

REPRIEVE trial: People with HIV are at increased risk of cardiovascular events due to noncalcified coronary plaque (NCP); pitavastatin reduces MACE and NCP volume, likely through collagen pathways, independent of LDL-C levels. ja.ma/4g5VBWZ REPRIEVE Trial

A #NewManuscript from the REPRIEVE Trial suggests a novel mechanism for plaque stabilization with statins through activation of collagen in people with HIV. Read the full article in JAMA Cardiology tinyurl.com/2b3ehdp7@MKolo… NIH NHLBI MassGeneral News NIAID News

In a new JAMA Cardiology study, researchers from REPRIEVE Trial and colleagues found an additional mechanism behind statin therapy's heart-related benefits in people with HIV. Read more: massgeneralbrigham.org/en/about/newsr… 10.1001/jamacardio.2024.4115 Steve Grinspoon

Taking a statin can help stabilize coronary artery plaque, reducing the risk that it will rupture and cause a heart attack or stroke, according to the latest findings from the REPRIEVE Trial #HIV heart study. poz.com/article/statin…

A #NewPublication from REPRIEVE finds that current ASCVD risk models underestimate cardiovascular events in women and Black men in high income countries, and overestimate events for PWH in low- and middle-income countries. Read more in Lancet HIV: doi.org/10.1016/S2352-…

Thank you to MassGeneral News for their coverage of our recent publication in #LancetHIV! These important findings allow researchers to fine-tune cardiovascular disease prediction models for people living with HIV. Read the full press release here: massgeneral.org/news/press-rel…

REPRIEVE trial: People with HIV are at increased risk of cardiovascular events due to noncalcified coronary plaque (NCP); pitavastatin reduces MACE and NCP volume, likely through collagen pathways, independent of LDL-C levels. ja.ma/3FGp2Sa REPRIEVE Trial

A #NewManuscript from REPRIEVE characterized factors associated with MACE, including heart attacks and strokes, among PWH. Notably, female sex did not appear to protect against MACE. Read the full publication at doi.org/10.1093/cid/ci…. MassGeneral Medicine Harvard CBAR